Comparative Pharmacology
Head-to-head clinical analysis: TAZVERIK versus XPOVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZVERIK versus XPOVIO.
TAZVERIK vs XPOVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), blocking the nuclear export of tumor suppressor proteins (e.g., p53, IκB) and growth regulators, leading to their nuclear accumulation and reactivation, thereby inducing apoptosis in cancer cells.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
XPOVIO (selinexor) is administered orally at a dose of 80 mg (four 20 mg tablets) on days 1 and 3 of each week for multiple myeloma. For diffuse large B-cell lymphoma, the recommended dose is 60 mg (three 20 mg tablets) on days 1 and 3 of each week.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Terminal half-life ranges from 6 to 10 hours (mean ~7.5 h) in patients with relapsed/refractory multiple myeloma; supports twice-weekly dosing with food.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Primarily metabolized by CYP3A4 and other pathways; <1% excreted unchanged in urine; fecal excretion accounts for ~80% of total clearance, with renal elimination minimal (<2% of dose).
Category C
Category C
Antineoplastic, EZH2 Inhibitor
Antineoplastic